A phase I trial of ADS-4101 for the treatment of partial onset epileptic seizures in healthy volunteers

Trial Profile

A phase I trial of ADS-4101 for the treatment of partial onset epileptic seizures in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Lacosamide (Primary) ; Lacosamide
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Apr 2018 Results of two phase 1 studies (CTP: 278641 and CTP:285253) assessing pharmacokinetic evaluations of ADS-4101 (Lacosamide) Modified Release Capsules versus Lacosamide immediate release presented at the 70th Annual Meeting of the American Academy of Neurology
    • 05 Dec 2017 Results assessing safety and efficacy presented at the 71st Annual Meeting of the American Epilepsy Society
    • 02 Nov 2017 According to an Adamas Pharmaceuticals media release, data will be presented at the American Epilepsy Society Annual Meeting in December 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top